Minerva Neurosciences Company Profile (NASDAQ:NERV)

About Minerva Neurosciences (NASDAQ:NERV)

Minerva Neurosciences logoMinerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $302.82 million
  • Outstanding Shares: 36,704,000
Average Prices:
  • 50 Day Moving Avg: $9.14
  • 200 Day Moving Avg: $8.89
  • 52 Week Range: $6.50 - $14.92
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.91
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.90 per share
  • Price / Book: 2.83
Profitability:
  • EBIDTA: ($32,900,000.00)
  • Return on Equity: -30.21%
  • Return on Assets: -24.21%
Debt:
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 6.64%
  • Quick Ratio: 6.64%
Misc:
  • Average Volume: 304,570 shs.
  • Beta: 1.73
  • Short Ratio: 13.32
 

Frequently Asked Questions for Minerva Neurosciences (NASDAQ:NERV)

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc (NASDAQ:NERV) issued its quarterly earnings data on Thursday, May, 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.01. View Minerva Neurosciences' Earnings History.

Where is Minerva Neurosciences' stock going? Where will Minerva Neurosciences' stock price be in 2017?

2 brokers have issued 1 year target prices for Minerva Neurosciences' shares. Their predictions range from $17.00 to $20.00. On average, they expect Minerva Neurosciences' stock price to reach $18.50 in the next year. View Analyst Ratings for Minerva Neurosciences.

What are analysts saying about Minerva Neurosciences stock?

Here are some recent quotes from research analysts about Minerva Neurosciences stock:

  • 1. According to Zacks Investment Research, "Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. " (5/16/2017)
  • 2. Jefferies Group LLC analysts commented, "We believe NERV's two candidates MIN-101 and -202 offer upside to shares. MIN-101, designed to treat negative symptoms in schizophrenia, an unmet need, has demonstrated stat sig benefits in PIIb. MIN-202, partnered with JNJ, may offer an effective tx to insomnia with fewer side effects, and has demonstrated positive data in PIIa with stat sig improvements in key sleep parameters. We assume with Buy and $17 PT." (3/6/2017)

Who are some of Minerva Neurosciences' key competitors?

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the folowing people:

  • Marc D. Beer, Independent Chairman of the Board
  • Remy Luthringer Ph.D., President, Chief Executive Officer, Director
  • Geoffrey Race, Executive Vice President and Chief Financial Officer
  • Joseph Reilly, Chief Operating Officer, Vice President
  • Frederick Ahlholm CPA, Chief Accounting Officer, Vice President
  • Mark Levine, Vice President, General Counsel, Secretary
  • Francesco de Rubertis Ph.D., Independent Director
  • David J. Kupfer M.D., Independent Director
  • Fouzia Laghrissi-Thode M.D., Independent Director
  • Michele Ollier M.D., Independent Director

How do I buy Minerva Neurosciences stock?

Shares of Minerva Neurosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Minerva Neurosciences' stock price today?

One share of Minerva Neurosciences stock can currently be purchased for approximately $8.20.


MarketBeat Community Rating for Minerva Neurosciences (NASDAQ NERV)
Community Ranking:  2.5 out of 5 (  )
Outperform Votes:  71 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  141
MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Minerva Neurosciences (NASDAQ:NERV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.50 (125.61% upside)

Analysts' Ratings History for Minerva Neurosciences (NASDAQ:NERV)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/1/2017JMP SecuritiesReiterated RatingOutperform$17.00 -> $20.00LowView Rating Details
3/6/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$17.00N/AView Rating Details
(Data available from 7/20/2015 forward)

Earnings

Earnings History for Minerva Neurosciences (NASDAQ:NERV)
Earnings by Quarter for Minerva Neurosciences (NASDAQ:NERV)
Earnings History by Quarter for Minerva Neurosciences (NASDAQ NERV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.30)($0.30)ViewListenView Earnings Details
3/13/2017Q4 2016($0.25)($0.27)ViewN/AView Earnings Details
11/3/2016Q316($0.21)($0.24)ViewListenView Earnings Details
8/4/2016Q116($0.30)($0.18)ViewListenView Earnings Details
5/3/2016Q1($0.33)($0.29)ViewListenView Earnings Details
3/14/2016Q4($0.31)($0.34)ViewListenView Earnings Details
11/5/2015Q315($0.43)($0.24)ViewListenView Earnings Details
8/5/2015Q215($0.53)($0.27)ViewN/AView Earnings Details
3/26/2015Q414($0.53)($0.40)ViewN/AView Earnings Details
11/6/2014Q3 2014($2.30)($1.53)ViewN/AView Earnings Details
8/7/2014Q2($0.41)($2.33)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Minerva Neurosciences (NASDAQ:NERV)
2017 EPS Consensus Estimate: ($1.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.30)($0.30)($0.30)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.47)($0.47)($0.47)
Q4 20171($0.48)($0.48)($0.48)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Minerva Neurosciences (NASDAQ:NERV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Minerva Neurosciences (NASDAQ:NERV)
Insider Ownership Percentage: 21.60%
Institutional Ownership Percentage: 70.07%
Insider Trades by Quarter for Minerva Neurosciences (NASDAQ:NERV)
Institutional Ownership by Quarter for Minerva Neurosciences (NASDAQ:NERV)
Insider Trades by Quarter for Minerva Neurosciences (NASDAQ:NERV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/20/2017Marc D BeerDirectorBuy50,000$8.12$406,000.00View SEC Filing  
2/6/2017Geoff RaceCFOSell21,450$11.02$236,379.00View SEC Filing  
2/6/2017Remy LuthringerCEOSell34,281$11.02$377,776.62View SEC Filing  
1/11/2017Joseph H ReillyCOOSell1,600$12.03$19,248.00View SEC Filing  
1/4/2017Mark S LevineSVPSell17,500$12.00$210,000.00View SEC Filing  
12/27/2016Frederick W AhlholmSVPSell17,000$12.51$212,670.00View SEC Filing  
8/10/2016Venture Associates L Index IIIMajor ShareholderSell1,000,000$10.00$10,000,000.00View SEC Filing  
6/21/2016David KupferDirectorBuy55,635$10.84$603,083.40View SEC Filing  
3/17/2016David KupferDirectorBuy181,488$5.51$999,998.88View SEC Filing  
3/18/2015Care Capital Iii LlcMajor ShareholderSell1,206,700$5.75$6,938,525.00View SEC Filing  
3/18/2015Rubertis Francesco DeDirectorBuy202,634$4.81$974,669.54View SEC Filing  
3/13/2015& Johnson JohnsonMajor ShareholderBuy607,903$4.81$2,924,013.43View SEC Filing  
1/26/2015Care Capital Iii LlcMajor ShareholderSell482,112$5.11$2,463,592.32View SEC Filing  
1/8/2015Care Capital Iii LlcMajor ShareholderSell531,808$7.38$3,924,743.04View SEC Filing  
7/7/2014Care Capital Iii LlcMajor ShareholderBuy737,500$6.00$4,425,000.00View SEC Filing  
7/7/2014Michele OllierDirectorBuy1,620,833$6.00$9,724,998.00View SEC Filing  
7/1/2014Coelho Rogerio VivaldiCEOBuy41,667$6.00$250,002.00View SEC Filing  
7/1/2014Frederick W AhlholmCAOBuy10,000$6.00$60,000.00View SEC Filing  
7/1/2014Geoff RaceCFOBuy33,333$6.00$199,998.00View SEC Filing  
7/1/2014Heek G Jan VanDirectorBuy3,333$6.00$19,998.00View SEC Filing  
7/1/2014Joseph H ReillyInsiderBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Minerva Neurosciences (NASDAQ:NERV)
Latest Headlines for Minerva Neurosciences (NASDAQ:NERV)
Source:
DateHeadline
finanznachrichten.de logoMINERVA NEUROSCIENCES INC
www.finanznachrichten.de - July 6 at 3:43 PM
finance.yahoo.com logoMinerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - July 6 at 7:18 AM
americanbankingnews.com logo Minerva Neurosciences, Inc (NERV) Given $17.00 Average Target Price by Brokerages
www.americanbankingnews.com - June 29 at 8:52 PM
finance.yahoo.com logoMinerva Neurosciences Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - June 29 at 6:06 AM
finance.yahoo.com logoMinerva On Track to Initiate Phase III Schizophrenia Study
finance.yahoo.com - June 27 at 6:35 AM
nasdaq.com logoMinerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in
www.nasdaq.com - June 23 at 7:18 PM
finance.yahoo.com logoMinerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia
finance.yahoo.com - June 23 at 8:22 AM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Stock Rating Reaffirmed by JMP Securities
www.americanbankingnews.com - June 1 at 7:58 PM
247wallst.com logoWhy Minerva Shares Are Climbing
247wallst.com - June 1 at 7:38 PM
finanznachrichten.de logoMinerva Neurosciences, Inc.: Minerva Announces Amended Agreement for MIN-202 in Insomnia
www.finanznachrichten.de - May 31 at 7:09 PM
finance.yahoo.com logoMinerva Announces Amended Agreement for MIN-202 in Insomnia
finance.yahoo.com - May 31 at 7:09 PM
finance.yahoo.com logoMinerva Neurosciences to Present at Jefferies 2017 Healthcare Conference on June 6, 2017
finance.yahoo.com - May 30 at 6:28 PM
americanbankingnews.com logo Minerva Neurosciences Inc (NERV) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - May 29 at 4:20 PM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - May 29 at 3:28 PM
americanbankingnews.com logo Brokerages Expect Minerva Neurosciences Inc (NERV) Will Announce Earnings of -$0.35 Per Share
www.americanbankingnews.com - May 29 at 8:24 AM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - May 23 at 3:08 PM
seekingalpha.com logoA Deep Dive Into Minerva Neurosciences' Pipeline
seekingalpha.com - May 16 at 6:31 PM
reuters.com logoBRIEF-Minerva Neurosciences announces outcome of meeting with FDA
www.reuters.com - May 16 at 6:31 PM
zacks.com logoMinerva (NERV) Provides Phase III Development Strategy for MIN-101
www.zacks.com - May 16 at 6:31 PM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - May 16 at 7:34 AM
streetinsider.com logoMinerva Neurosciences (NERV) Reports Outcome of End-of-Phase 2 Meeting With FDA
www.streetinsider.com - May 15 at 6:08 PM
finance.yahoo.com logoMinerva Announces Outcome of End-of-Phase 2 Meeting With FDA
finance.yahoo.com - May 15 at 10:13 AM
finance.yahoo.com logoMinerva Provides Update on Phase 3 Design and Development Strategy for MIN-101
finance.yahoo.com - May 15 at 10:13 AM
finance.yahoo.com logoMinerva Neurosciences stock rises 7% on plans to advance schizophrenia drug to late-stage trials
finance.yahoo.com - May 15 at 10:13 AM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Releases Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - May 8 at 5:44 PM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 6 at 9:08 AM
reuters.com logoBRIEF-Minerva Neurosciences Q1 loss per share $0.30
www.reuters.com - May 4 at 6:53 PM
finance.yahoo.com logoInvestor Network: Minerva Neurosciences Inc to Host Earnings Call
finance.yahoo.com - May 4 at 11:25 AM
finance.yahoo.com logoMinerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates
finance.yahoo.com - May 4 at 11:25 AM
marketbeat.com logoMinerva Neurosciences reports 1Q loss
marketbeat.com - May 4 at 8:46 AM
americanbankingnews.com logoMinerva Neurosciences (NERV) Receives Daily News Sentiment Rating of 0.31
www.americanbankingnews.com - May 3 at 11:18 PM
americanbankingnews.com logo Brokerages Anticipate Minerva Neurosciences Inc (NERV) to Announce -$0.30 EPS
www.americanbankingnews.com - May 3 at 8:24 PM
americanbankingnews.com logoMinerva Neurosciences (NERV) Earns News Sentiment Rating of 0.31
www.americanbankingnews.com - April 29 at 1:19 AM
nasdaq.com logoMinerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4,
www.nasdaq.com - April 28 at 12:19 AM
finance.yahoo.com logoMinerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4, 2017
finance.yahoo.com - April 27 at 9:57 AM
americanbankingnews.com logoMinerva Neurosciences (NERV) Receiving Somewhat Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 24 at 9:03 PM
finance.yahoo.com logoLifeSci Capital Initiates Coverage of Minerva Neurosciences
finance.yahoo.com - April 18 at 6:10 PM
americanbankingnews.com logoMinerva Neurosciences (NERV) Earning Somewhat Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 15 at 2:55 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Minerva Neurosciences Inc (NERV) to Announce -$0.30 EPS
www.americanbankingnews.com - April 12 at 4:09 PM
bizjournals.com logoFormer Aegerion chief Marc Beer to launch new Boston biotech
www.bizjournals.com - April 7 at 11:26 AM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - April 5 at 9:52 PM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 5 at 9:01 AM
americanbankingnews.com logoZacks Investment Research Upgrades Minerva Neurosciences Inc (NERV) to "Hold"
www.americanbankingnews.com - March 30 at 11:24 PM
globenewswire.com logoMinerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market ... - GlobeNewswire (press release)
globenewswire.com - March 23 at 7:18 PM
streetinsider.com logoMinerva Neurosciences (NERV) Reports Exercise of Warrants, Purchase of Common Stock by Chairman
www.streetinsider.com - March 21 at 11:40 PM
nasdaq.com logoMinerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open
www.nasdaq.com - March 21 at 6:40 PM
finance.yahoo.com logoMinerva Neurosciences Announces Recent Exercise of Warrants by Institutional Stockholders and Open Market Purchase of Common Stock by Chairman of Its Board of Directors
finance.yahoo.com - March 21 at 6:40 PM
americanbankingnews.com logoMinerva Neurosciences Inc (NERV) Director Buys $406,000.00 in Stock
www.americanbankingnews.com - March 21 at 1:25 PM
biz.yahoo.com logoMINERVA NEUROSCIENCES, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - March 21 at 11:34 AM
thestreet.com logoBiotech Premarket Movers: Esperion, Minerva and BioCryst
www.thestreet.com - March 21 at 11:34 AM

Social

Chart

Minerva Neurosciences (NERV) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by MarketBeat.com Staff